Would you consider re-trial with alternative immune checkpoint inhibitor therapy for a patient with metastatic TFE3-rearranged renal cell carcinoma who progressed on nivolumab/cabozantinib?

Would you consider re-trial with alternative immune checkpoint inhibitor therapy for a patient with metastatic TFE3-rearranged renal cell carcinoma who progressed on nivolumab/cabozantinib?

• Yes, would trial pembrolizumab +/- TKI
• Yes, would consider dual ICI
• No, would not rechallenge with ICI
• Other